Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan ConsortiumTaizo Uchimoto, Haruhito Azuma, Masanobu Saruta et al.|International Journal of Clinical Oncology|2024Cited by 12
Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortiumTaizo Uchimoto, Haruhito Azuma, Kengo Iwatsuki et al.|International Journal of Clinical Oncology|2025Cited by 4
Real-world Outcomes of Enfortumab Vedotin in Elderly Patients With Metastatic Urothelial CarcinomaKyosuke Nishio, Kazumasa Komura, Kensuke Hirosuna et al.|Anticancer Research|2025Cited by 2
Deciphering RCC immunotherapy outcomes: insights from a Japanese multi-institutional study on the CANLPH score’s impactTatsuo Fukushima, Haruhito Azuma, Takuya Tsujino et al.|World Journal of Urology|2025Cited by 1